Latest Foreign Investment Review News

Aquirian Limited has completed a strategic review of its Wubin Energetics Precinct and entered a framework agreement with Hongda Civil Blasting Group to establish a joint venture for an automated electronic detonator facility in Western Australia.

Pepper Money and KKR have agreed to acquire Westpac’s RAMS home loan portfolio, marking a significant move in Australia’s mortgage servicing landscape. The $21.4 billion portfolio acquisition aligns with Pepper Money’s strategy to expand its capital-light servicing business.

Toro Energy has agreed to be acquired by IsoEnergy in a deal valuing Toro shares at a 79.7% premium, combining uranium assets across Australia, Canada, and the US. The transaction promises enhanced scale and exposure to tier-one uranium projects, pending shareholder and regulatory approvals.

The Treasurer has expressed preliminary concerns that Cosette Pharmaceuticals’ proposed acquisition of Mayne Pharma could harm Australia’s economy, citing plans to close a key Adelaide manufacturing site. Mayne Pharma disputes these claims and urges a resolution before the scheme deadline.

PhosCo has received a €1 million grant from the European Bank for Reconstruction and Development alongside a $1.1 million investment from its Managing Director, fueling optimisation efforts ahead of the Gasaat Phosphate Project’s bankable feasibility study.

Suzerain Investments Holdings Limited has initiated an off-market takeover bid for all remaining shares of Entertainment Rewards Ltd (EAT) at $0.022 per share, a substantial premium over recent trading prices. The offer comes with unanimous support from EAT's Independent Board Committee, subject to regulatory approvals and an independent expert's fairness opinion.

Pearl Gull Iron Limited has entered a binding agreement to sell its Cockatoo Island Project for A$4.5 million in cash, a 4% equity interest in Crestlink Pty Ltd, and royalties on extracted materials, with completion expected in Q4 2025.

Mad Paws Holdings Limited convened a pivotal Scheme Meeting to seek shareholder approval for its $61.5 million acquisition by Rover Group, Inc., with the Board unanimously backing the deal. Key conditions precedent have been met, setting the stage for final court approval and scheme implementation in November.

Apiam Animal Health Limited has entered a binding agreement with Adamantem Capital Fund II for a $228.4 million acquisition via a scheme of arrangement, offering shareholders a significant premium and flexible cash or scrip consideration options.

Mayne Pharma has announced the rescheduling of its Supreme Court hearing to November 3, 2025, to approve the acquisition scheme by Cosette Australia BidCo, pending Foreign Investment Review Board approval.

United States Antimony Corporation has made a non-binding indicative offer to acquire Larvotto Resources at a significant premium, proposing a strategic merger focused on antimony supply chain security and growth.

Mayne Pharma’s planned acquisition by Cosette Pharmaceuticals faces a delay as the Foreign Investment Review Board postpones its decision, potentially pushing back key court proceedings.